Amylin is a pancreatic B-cell hormone that plays an important role in the control of nutrient fluxes because it reduces food intake, slows gastric emptying, and reduces postprandial glucagon secretion. These actions seem to depend on a direct effect on the area postrema (AP). Subsequent to area AP activation, the amylin signal is conveyed to the forebrain via distinct relay stations. Within the lateral hypothalamic area, amylin diminishes the expression of orexigenic neuropeptides. Recent studies suggest that amylin may also play a role as a long term, adiposity signal. Similar to leptin or insulin, an infusion of amylin into the brain resulted in lower body weight gain than in controls, irrespective of the starting body weight. Interestingly, preliminary data also suggest that rats fed an energy-dense diet develop resistance to central amylin. In addition to amylin's action to control meal termination and to act as a potential adiposity signal, amylin and its agonist salmon calcitonin have recently been shown to increase energy expenditure under certain conditions. In summary, amylin may be an interesting target as a body weight lowering drug. In fact, recent studies provide evidence that amylin, especially when combined with other anorectic hormones (for example, peptide YY and leptin) has beneficial long-term effects on body weight.
Introduction
Amylin is a pancreatic B-cell hormone co-released with insulin in response to food intake. Amylin reduces eating, gastric acid secretion, limits the rate of gastric emptying, and diminishes pancreatic glucagon secretion. 1 These actions, in particular amylin's effect on gastric emptying and glucagon secretion, are the basis for the use of amylin analogs in the treatment of type 2 diabetes mellitus. 2, 3 Regarding the control of eating, amylin is among the more interesting hormones affecting food intake. In addition to amylin's effect to control meal size, several studies suggest that amylin may also be involved in the long-term control of food intake and body weight, sharing characteristics with adiposity signals. 4, 5 Amylin is a satiating signal
The best-studied function of amylin is its role as a hormone contributing to meal termination. 1, 6 Amylin shares the characteristics typical of satiating hormones such as cholecystokinin (CCK). 7 First, amylin is released during food ingestion, and it dose dependently reduces meal size. Second, after a single peripheral injection, amylin has a rapid onset and brief duration of action. Third, the anorectic action of amylin appears to be specific, as amylin does not reduce feeding by producing a conditioned taste aversion or by an unspecific effect (for example, via a reduction in drinking). The lowest dose of exogenous amylin that produced a significant reduction in feeding yielded plasma amylin levels that were only slightly higher than the concentrations measured postprandially. Finally, amylin seems to be a physiological control of meal size because amylin antagonists produce the opposite effect, that is, they increase eating, mainly via a meal size effect.
8,9
Primary site for amylin-mediated satiation
Experimental evidence supports the idea that the satiating effect of peripheral amylin is mediated by direct humoral action on the area postrema (AP) in the hindbrain (for example Mollet et al. 9 , Lutz et al. 10 and Lutz et al.
11
), an area that lacks a functional blood-brain barrier. Behavioral studies showed that whereas amylin's effect is abolished in rats with lesions in the AP/NTS region, 10, 11 none of the techniques that block neural afferent information from the periphery to the brain was able to abolish the anorectic action of peripheral amylin (for example, Morley et al. 12 ). An infusion of the amylin antagonist AC 187 into the AP increased food intake due to an increase in meal size. AC 187 infused into the AP also reduced the anorectic effect of peripheral amylin. 9 Feeding studies were complemented by electrophysiological and immunohistochemical studies. 6, 13, 14 A direct, dose-dependent stimulating effect of amylin on AP neurons underlines their sensitivity to amylin. Further, peripheral amylin produced a strong expression of the immediate early gene product c-Fos protein as a marker of neuronal activation in AP neurons. The latter may be linked to the generation of cGMP in amylin target cells. 6 Recently, we unexpectedly observed that low doses of amylin induced very little c-Fos in the AP in ad libitum chow fed rats, but amylin caused a strong c-Fos expression in fooddeprived rats and in rats that received a nutrient-deficient non-energetic mash (NCM). After supplementation of NCM with single nutrients, rats fed NCM supplemented with glucose or fat displayed an equally strong amylin-induced activation as fasted rats or rats fed plain NCM. c-Fos expression was significantly lower when rats were fed a protein supplemented NCM. Further, amylin failed to reduce food intake in NCM/protein-fed rats, whereas amylin caused a reduction in feeding when animals received NCM, NCM/ glucose, or NCM/fat. Interestingly, amylin effectively reduced food intake in ad libitum chow-fed rats despite the lack of a prominent amylin-induced c-Fos expression in the AP under these conditions, perhaps pointing to a partially Fosindependent action of amylin. Overall, amylin's anorectic potential may be attenuated by large amounts of protein in the diet, whereas this effect appears to be overridden when the amount of carbohydrates and fat is high relative to the protein content such as in standard chow. 15 Pathways beyond the AP Peripheral administration of amylin elicits a strong c-Fos response in projection areas of the AP, that is, in the NTS, the lateral parabrachial nucleus (lPBN), the central nucleus of the amygdala, and the bed nucleus of the stria terminalis. 13, 14 Their activation seems to be secondary to an action of amylin on AP neurons. Activation of the lPBN, but not the central nucleus of the amygdala, seems to be a necessary part in the signaling cascade for amylin's anorectic effect. 16 The exact pathways used by amylin beyond the lPBN are currently under investigation. Previously, we provided evidence that the lateral hypothalamic area may play a role in amylin's anorectic effect. 14, 17 Recent studies with anterograde and retrograde neuronal tracers support the idea that amylinactivated neurons in the lPBN project to the subregion of the lateral hypothalamic area that is affected by amylin administration (C Potes, T Riediger, TA Lutz, unpublished).
Interaction of amylin with other hormones
Amylin and CCK Food intake leads to the release of a multitude of gastrointestinal peptide hormones. This 'cocktail' of hormones (for example, amylin, CCK, peptide YY (PYY), etc.) may be a more precise signal to the brain regarding the amount and composition of ingested food than that of a single signal. Relatively little is known about the specific release of the various gastrointestinal feedback signals and their interaction. We studied recently the interaction of amylin and CCK and found that amylin seems to be a necessary modulator of CCK's anorectic action because amylin knockout mice, for example, have a blunted feeding response to exogenous CCK that can be rescued by the injection of low, subthreshold doses of amylin.
18,19
Amylin and leptin or insulin Adiposity signals modulate the effect of satiating hormones, that is, both leptin and insulin affect the potency of CCK to reduce meal size (reviewed in Woods 5 ). Eiden et al. 20 showed that rodent models with a defective leptin signaling system have a reduced response to anorectic doses of the amylin agonist salmon calcitonin (sCT). Recently, we showed that food intake was reduced more in rats receiving a third ventricular (I3vt) administration of leptin and an intraperitoneal injection of amylin than by either peptide alone. Further, a subthreshold dose of I3vt insulin significantly enhanced the response to peripheral amylin, and combined peripheral administration of subthreshold doses of insulin and amylin significantly reduced food intake in rats. 21, 22 This may indicate that the adiposity signals leptin and insulin interact with amylin to reduce food intake. 21 In contrast, we 21 and others 23 found no evidence for an interaction between the orexigenic hormone ghrelin and amylin.
Pharmacological tests with cocktail treatments including amylin
The first clinical tests involving amylin that were part of a program for the development of antidiabetic drugs showed that in patients who received insulin plus amylin replacement (in the form of the amylin analog pramlintide), food intake and body weight were decreased more than in patients receiving insulin alone. 3 Follow-up studies indicated that amylin may be an interesting option in the treatment of obesity. Most pronounced effects were observed when amylin was combined with leptin, or in a triple combination with PYY and leptin. 24, 25 Food intake and energy expenditure by amylin TA Lutz
Summary of the central nervous system mechanisms mediating amylin's effect on food intake
We propose the following central nervous system pathway. Amylin released from pancreatic B-cells in response to food intake seems to have a direct hormonal action on AP neurons that project via the NTS and lPBN to higher brain centers. Preliminary data indicate that amylin-activated lPBN neurons project to a specific lateral hypothalamic area subregion. Some studies also indicate that the ventromedial hypothalamus may be involved in this pathway via histaminergic transmission. 26 Site and mechanism of interaction between amylin and other anorectic hormones (for example, CCK, PYY, leptin, insulin) remain to be established.
Amylin as an adiposity signal
Amylin differs from pure satiating signals because it may also play a role as an adiposity signal. 4, 10, 27, 28 Similar to leptin and insulin, the basal levels of amylin depend on the prevailing body adiposity. In rats, chronic amylin infusion lowers food intake and body weight gain by reducing body adiposity. Chronic peripheral or central infusion of amylin antagonists increases body weight with a major effect on an increase in body fat. 4 Therefore, the effect of a chronic modulation of the central amylin signaling system seems to be similar to that of leptin or insulin. Chavez et al. 29 showed that during chronic central insulin infusion, previously food-deprived rats and ad libitum fed rats attained a similar level of body weight that was markedly below the level of respective saline infused control rats. On the basis of this study, we injected rats once daily with the amylin agonist sCT or saline for nine consecutive days. Half of the saline and half of the sCT-treated rats did not receive food for the first two days into the study. Similar to the study by Chavez et al., 29 both groups of animals caught up in body weight with their counterparts that had not been food deprived but received the same treatment (sCT or saline). Similarly, in rats chronically infused with amylin or saline into the third cerebral ventricle, all amylin-treated animals achieved a similar body weight at the end of infusion that was significantly below that of saline controls. These studies suggest that both central insulin and amylin determine the level of body weight maintained by the animal. In a third experiment, we overfed some of the rats before amylin infusion by offering them a calorie-dense diet (Ensure) in addition to standard chow. To our surprise, animals overfed for 3 weeks appeared to be resistant to the body weight lowering effect of amylin. The underlying mechanisms are currently under investigation (PY Wielinga, TA Lutz, unpublished). At present, it is difficult to judge how the quantitative contribution of amylin to the control of body weight compares with that of leptin or insulin. The amylin-deficient mouse 6 clearly shows less of an obese phenotype than, for example, the leptin-deficient ob/ob mouse. This may imply that under conditions when baseline amylin levels are normal and when other adiposity signal systems are functional, the relevance of amylin as an adiposity signal is minor. However, when the leptin and insulin feedback signaling systems are deficient, amylin may play some role as an adiposity signal and at least partly take over the function of leptin and insulin. 30 
Amylin increases energy expenditure
The adiposity signal leptin is known to increase energy expenditure under appropriate conditions. On the basis of previous reports that amylin may increase body temperature, we recently investigated whether amylin or sCT shares leptin's effects on energy expenditure. Although the acute administration of amylin failed to affect energy expenditure in rats, the amylin agonist sCT significantly stimulated energy expenditure in fasted animals. 31 Chronic amylin administration was shown to either increase energy expenditure, at least when expressed relative to body weight, 32 or prevent the decrease in energy expenditure that was seen in animals whose food intake was yoked with that of amylintreated rats (PY Wielinga, TA Lutz, unpublished). In any case, amylin seems to prevent the compensatory decrease in energy expenditure normally seen in animals that eat less.
Summary
Amylin seems to be a physiological control of meal size. Most studies indicate that the effect of peripheral amylin is centrally mediated via the AP. Chronic exposure to amylin decreases food intake and body weight gain. Next to its induction of satiation, amylin may also constitute one of the body's adiposity signals. Amylin analogs are under clinical consideration for their effect to reduce food intake and body weight in humans, especially in type 2 diabetics.
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